Samsung Bioepis

Evolution step-up growth trajectory upward trajectory
Pharma

How biosimilar developers are embracing next phase of US market

Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
Asia

China's BCI nod, AZ, Astellas—Fierce Pharma Asia

Mar 20, 2026 8:00am
NuProbe

Sandoz expands biosimilar collaboration with Samsung Bioepis

Mar 18, 2026 11:05am
drug prices biologics drug costs IRA money cash payment co-pay

Inside the turning tides of the US biosimilar market

Jan 8, 2026 9:00am
newspaper

Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia

Oct 31, 2025 8:20am
Asia

Pfizer CEO, Otsuka, Novartis-MSN—Fierce Pharma Asia

Jun 13, 2025 9:18am